Blood Adv
Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia.   

Related Questions

Given the rarity of this diagnosis (5-7% of all AL amyloidosis cases), and the prognostic and clinical differences when compared to non IgM-AL am...